Overview
CDK4/6 inhibitors combined with endocrine therapy are the cornerstone of first-line treatment for hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- MBC). This large-scale real-world study leverages the Flatiron Health Research Database to examine the real-world use of abemaciclib to improve outcomes for patients with node-positive, hormone receptor-positive (HR+), HER2-negative early breast cancer.
This research used the Flatiron Health EHR-derived database to analyze data from 354 patients who began treatment with abemaciclib at the recommended dose from Oct 2021 - Feb 2023. The study found that 88.1% of patients continued treatment beyond three months and 50.8% required dose reductions to manage early side effects. Importantly, 93.3% of those who had dose reductions continued their treatment, highlighting the effectiveness of dose adjustments in maintaining therapy persistence.
Why this matters
This research provides critical insights into the practical administration of abemaciclib in a real-world setting, demonstrating that timely dose adjustments can effectively manage adverse events and support patients in continuing treatment. By maintaining high persistence rates, particularly among those who experience early side effects, healthcare providers can optimize therapy outcomes for patients with early breast cancer. These findings use real-world evidence to emphasize the importance of personalized treatment strategies and proactive management of side effects, and underscores the potential of real-world data to enhance understanding and inform clinical practice in cancer treatment.